“Phase 1a/1b Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis”

CUMC IRB #AAAM5108
Protocol (v.3 / 5Mar14)
IND #117316

Suzanne Lentzsch, MD, PhD
August 13, 2014
mAb 11-1F4

- murine mAb 11-1F4
  - Recognizes human light-chain related fibrils via amyloid-associated conformational epitope
  - Speculate that 11-1F4 interferes with lag/hyperbolic growth phase of fibril formation

- Activity:
  - Binds/opsonizes to fibrils
  - Attracts and activates neutrophils
  - Proteolysis by neutrophil-derived endopeptidases
Primary Objectives

• Establish the maximum tolerated dose (up to 500 mg/m$^2$) of 11-1F4
Secondary Objectives

- Demonstrate reduction in amyloid burden, as evidenced by a decrease in affected organomegaly and/or improved organ function
- Determine the pharmacokinetics of 11-1F4 when given as a single IV infusion (phase 1a) or as a series of weekly IV infusions (phase 1b)
- Obtain additional safety data of 11-1F4 when given as a single IV infusion or as a series of weekly IV infusions
Major Inclusion Criteria

- Confirmed diagnosis of AL amyloidosis based on accepted clinical/laboratory criteria
- > 21 years old
- Life expectancy > 3 months
- ECOG-specified performance status ≤ 3
- Have measurable, localized amyloid deposits (larynx, subcutaneous tissue, muscle, lung, lymph nodes) or clinically evident systemic disease (liver, kidney, heart, etc).
- Relapsed/refractory, unless they have declined or are not eligible for high-dose melphalan and autologous HSCT or any other standard therapy that has been known to be life-prolonging or life-saving
Major Inclusion Criteria (cont.)

- Organ function:
  - **Heart:**
    - Ventricular ejection fraction ≥ 40%
    - Intraventricular septal (IVS) thickness ≤ 25 mm (as determined by 2D echocardiography)
    - No history of sustained ventricular tachycardia (lasting longer than 30 sec) or cardiac arrest
  - **Kidney:**
    - 24-hr creatinine clearance ≥ 30 cc/min
  - **Liver:**
    - Alkaline phosphatase ≤ 3 x ULN
    - Bilirubin, ≤ 3.0 mg/dL
Major Exclusion Criteria

- Non-AL amyloidosis
- Renal failure (on dialysis)
- Involvement in an AL therapeutic trial within 6 mo.
- Females of child-bearing potential who are pregnant or breastfeeding
- ECOG > 3
- Seriously limited cardiac, renal, or hepatic function
- Uncontrolled infection or significant co-morbidity (e.g., uncontrolled diabetes, severe diarrhea that requires TPN)
- Prior exposure to a humanized anti-amyloid mAb
Treatment overview

- **Phase 1a**
  - Infusion x 1

- **Phase 1b**
  - Infusion x 4

  - **2 week interval** after 4th infusion to ensure that no untoward reaction has occurred before administering drug to next patient

  - Subjects from Phase 1a can be accrued to Phase 1b after completion of Week 8 assessment

*Amendment: include dose levels 0.125, 0.25, 0.5, 5 mg/m²*